The Advocacy Training Session

 

The first training for certification will include a
variety of topics to give advocates a well-grounded understanding of
methadone treatment, research, regulations and laws that protect
methadone patients and programs.

 

  1. Addiction
    and Methadone
    Tom Payte, MD (Drug Dependence
    Associates) and Joycelyn Woods, MA. (NAMA) The
    biological constructs of addiction will be explained in a way that
    can be understood by lay people (i.e. opiate receptors, Endorphins)
    Methadone dose and what is considered an adequate dose and why it is
    important and what methadone does to make you feel normal.
  2. Regulations
    and Accreditatio
    n
    C. Todd
    Rosendale (CSAT/DPT), Sharon Dow (Joint Commission), Bettye Harrison
    (CARF) and Joanne Page (COA).The new federal regulations will be explained:  What
    they are and how they relate to the state regulations? Accreditation
    and what an accreditation survey is, how it is done, and how
    advocates can be involved.
  3. The
    Different Faces of Advocacy

    Presenters to be announced.
    Advocates from around the country will explain what they do to
    advance the goals of methadone advocacy. This session will also
    explain the different types of advocacy that advocates are involved
    in.
  4. How
    to End Methadone Stigma
    Herman Joseph, Ph.D. The history of
    methadone stigma will be presented and how it has impacted methadone
    treatment and the recipients of it. A plan for advocates to work on
    for ending it will be revealed.
  5. Advocate
    Certification

    Walter Ginter (NAMA Training and Certification Director) What is certification and how it
    will professionalize those committed to methadone advocacy.  The Advocates Code of Ethics, the Goals of Methadone
    Advocacy, and Advocate Certification.

         Top

Similar Posts

  • |

    Antiviral Therapy

    Admin 07/04/2021

    HCV Info Fact 9 Nov 2003 Antiviral therapy has steadily improved over the last decade. The side effect profile of interferon-based therapies has remained largely unchanged. Recent data have suggested that improved adherence to combination regimens will favorable affect sustained virologic response rates. The minimal criteria recommended by the National Institutes of Health for candidates…

  • TRIPS Update

    Admin 08/29/2021

    TRIPS No Longer Operating This past Spring TRIPS the project that assists methadone patients to find an alternative site while traveling was closed. It happened very quickly and as you would expect created problems immediately. NAMA began receiving calls as early as March from patients trying to locate a program in the area that they…

  • |

    Pharmacological Agents Interacting With Methadone

    Admin 09/10/2021

    Information on NAMA’s website is not intended as medical advice for individual problems.   Appropriate medical professionals should be consulted regarding addiction and addiction recovery.   Pharmacologic Agents Clinical Signs and Symptoms Comments Drugs That Decrease Methadone Levels Rifampin, phenytoin, carbamazepine, butabarbital sodium, mephobarbital, phenobarbital, secobarbital, ethanol (chronic), disulfiram, urinary acidifiers, ascorbic acid Withdrawal signs Disulfiram…

  • |

    FOR IMMEDIATE RELEASE

    Admin 01/30/2022

    October 9, 2002 NIDA Contact: Michelle Person 301-443-6245 SAMHSA Contact: Leah Young 301-443-8956 NIDA Research and SAMHSA Physician Training Combine to Put Care for Opiate Dependence in Hands of Family Doctor. Buprenorphine, a new medication developed through more than a decade of research supported by the National Institute on Drug Abuse (NIDA), will now become…

  • Category: In Memoriam

    Admin 02/20/2023

    Paul Edward Bowman (1963-2021) December 3, 2021 NAMA Recovery is saddened to report the passing of a long-standing member of our Board of Directors. Paul Edward Bowman, Jr, 58, passed away on November 22, 2021. Paul was born in Boston, MA and lived most of his life in Quincy, MA. Paul served Massachusetts residents for…

  • Nominations Open for the 2022 Richard Lane/Robert Holden Advocacy Award!

    Admin 03/06/2023

    Nominations Open for the 2022 Richard Lane/Robert Holden Advocacy Award! NAMA Recovery    AATOD Lane Holden Award    May 1, 2022  |  0 Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first opioid treatment programs. In 1974, he became the Executive…